Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Takeda Zasocitinib TYK2 Phase III Shows Positive Psoriasis Results

Fineline Cube Dec 23, 2025
Company Drug

Lilly Imlunestrant Breast-Cancer EMBER-3 Shows 38% Risk Reduction

Fineline Cube Dec 23, 2025
Company Drug

Hansoh Pharmaceutical’s Phenylheptal Peptide Receives NMPA Approval for Anemia Treatment

Fineline Cube Jul 3, 2023

The National Medical Products Administration (NMPA) has issued a marketing approval for China-based Hansoh Pharmaceutical...

Company Drug

Sinocelltech Group Receives NMPA Approval for Bevacizumab Biosimilar for Multiple Cancers

Fineline Cube Jun 30, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received marketing approval from...

Company Deals

Cornerstone Robotics Secures RMB 800 Million in Funding for Surgical Robot Development

Fineline Cube Jun 30, 2023

Cornerstone Robotics, a leading surgical robot developer based in Shenzhen, has reportedly raised RMB 800...

Company Drug

Huadong Medicine Receives NMPA Approval for DR30206 Clinical Study in Advanced Solid Tumors

Fineline Cube Jun 30, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Policy / Regulatory

NHSA Unveils 2023 Work Plan for National Reimbursement Drug List Update

Fineline Cube Jun 30, 2023

The National Healthcare Security Administration (NHSA) has released the “Work Plan for the National Reimbursement...

Company Drug

Sinocelltech Group Receives NMPA Approval for COVID-19 Vaccine Bridging Phase II Study

Fineline Cube Jun 30, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has announced receiving approval from the National Medical Products...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Phase III Studies of Gallium Edotreotide Injection

Fineline Cube Jun 30, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Jacobio Pharma Reports Promising Clinical Results for KRAS G12C Inhibitor Gecirasib in CRC

Fineline Cube Jun 30, 2023

China-based Jacobio Pharma (HKG: 1167) has announced clinical results for its novel KRAS G12C inhibitor,...

Company Drug

Harbour BioMed’s Batoclimab for Generalized Myasthenia Gravis Accepted for NMPA Review

Fineline Cube Jun 30, 2023

Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands,...

Company Drug

Hansoh Pharmaceutical Gets NMPA Approval for HS-10518 Clinical Study in Endometriosis Pain

Fineline Cube Jun 30, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...

Medical Device

MicroPort MedBot’s Dragonfly Eye 3D Endoscopy Earns CE Mark for Intraperitoneal Procedures

Fineline Cube Jun 30, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that its in-house developed Dragonfly...

Company Deals

Merck KGaA Expands High-Purity Reagents Production in Nantong, China with EUR 70 Million Investment

Fineline Cube Jun 30, 2023

Germany-based Merck KGaA (NYSE: MRK) has announced plans to expand production capacity for highly-purified reagents...

Company Deals

Shanghai Pharmaceuticals’ MediTrust Health Partners with Yuanda Shuyang on Rare Disease Treatment Model

Fineline Cube Jun 29, 2023

Shanghai Pharmaceuticals Holding Co., Ltd’s (SHA: 601607, HKG: 2607) subsidiary, MediTrust Health, which specializes in...

Company Drug

Qilu Pharmaceutical’s Iruplinalkib Receives NMPA Approval for ALK+ NSCLC Treatment

Fineline Cube Jun 29, 2023

China-based Qilu Pharmaceutical has announced that its Category 1 chemical drug, iruplinalkib, an ALK inhibitor,...

Company Drug

Jiangsu Hengrui’s Oteseconazole (SHR8008) Approved by NMPA for Severe Vulvovaginal Candidiasis

Fineline Cube Jun 29, 2023

The National Medical Products Administration (NMPA) has granted approval to China-based Jiangsu Hengrui Pharmaceuticals Co.,...

Company Deals

WestGene Biopharma Secures $42 Million in Funding to Advance mRNA Therapeutics

Fineline Cube Jun 29, 2023

Chengdu-based mRNA specialist WestGene Biopharma has reportedly raised USD 42 million via a funding round,...

Company Deals

Pfizer Partners with CSPC Pharmaceutical to Localize Paxlovid in China

Fineline Cube Jun 29, 2023

US pharmaceutical major Pfizer (NYSE: PFE) has entered into a partnership with China-based CSPC Pharmaceutical...

Company Drug

EOC Pharma’s Lusutrombopag Receives NMPA Approval for Chronic Liver Disease Treatment

Fineline Cube Jun 29, 2023

China-based EOC Pharma Group has announced that its drug, lusutrombopag, has received marketing approval from...

Company Deals

Changchun BCHT Biotechnology to Acquire Full Stake in mRNA R&D Firm Transcend Biomedical

Fineline Cube Jun 29, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced its intention to invest in...

Company Drug

Jiangsu Simcere’s Edaravone, Borneol Sublingual Tablets for AIS Accepted by NMPA for Review

Fineline Cube Jun 29, 2023

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that the National Medical Products Administration...

Posts pagination

1 … 443 444 445 … 600

Recent updates

  • Takeda Zasocitinib TYK2 Phase III Shows Positive Psoriasis Results
  • Lilly Imlunestrant Breast-Cancer EMBER-3 Shows 38% Risk Reduction
  • IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully
  • Novartis MSD Sanofi TrumpRx Deal Targets Medicaid Pricing
  • Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Takeda Zasocitinib TYK2 Phase III Shows Positive Psoriasis Results

Company Drug

Lilly Imlunestrant Breast-Cancer EMBER-3 Shows 38% Risk Reduction

Company Drug

IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully

Company

Novartis MSD Sanofi TrumpRx Deal Targets Medicaid Pricing

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.